US 12,089,916 B2
Gastrointestinal tract detection methods, devices and systems
Sharat Singh, Rancho Santa Fe, CA (US); Mitchell Lawrence Jones, La Jolla, CA (US); and Christopher Loren Wahl, San Diego, CA (US)
Assigned to BIORA THERAPEUTICS, INC., San Diego, CA (US)
Filed by BIORA THERAPEUTICS, INC.
Filed on Mar. 24, 2020, as Appl. No. 16/827,807.
Application 16/827,807 is a continuation of application No. 15/835,303, filed on Dec. 7, 2017, granted, now 10,610,104.
Claims priority of provisional application 62/583,768, filed on Nov. 9, 2017.
Claims priority of provisional application 62/560,618, filed on Sep. 19, 2017.
Claims priority of provisional application 62/545,157, filed on Aug. 14, 2017.
Claims priority of provisional application 62/502,383, filed on May 5, 2017.
Claims priority of provisional application 62/478,753, filed on Mar. 30, 2017.
Claims priority of provisional application 62/434,320, filed on Dec. 14, 2016.
Claims priority of provisional application 62/431,297, filed on Dec. 7, 2016.
Prior Publication US 2020/0221954 A1, Jul. 16, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 5/00 (2006.01); A61B 5/07 (2006.01); A61B 5/145 (2006.01); A61B 10/00 (2006.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01); C12M 1/00 (2006.01); C12N 1/20 (2006.01); C12Q 1/04 (2006.01); C12Q 1/06 (2006.01); C12Q 1/10 (2006.01); G01N 1/10 (2006.01); G01N 1/20 (2006.01); G01N 1/38 (2006.01); G01N 21/76 (2006.01); G01N 33/483 (2006.01); G01N 33/487 (2006.01); G01N 33/58 (2006.01); A61B 5/01 (2006.01); A61B 5/03 (2006.01); A61B 5/1455 (2006.01)
CPC A61B 5/0071 (2013.01) [A61B 5/073 (2013.01); A61B 5/4238 (2013.01); A61B 5/4255 (2013.01); A61B 5/6861 (2013.01); A61B 10/0045 (2013.01); A61K 45/06 (2013.01); A61K 49/0019 (2013.01); A61K 49/0058 (2013.01); C12M 29/26 (2013.01); C12N 1/20 (2013.01); C12Q 1/045 (2013.01); C12Q 1/06 (2013.01); C12Q 1/10 (2013.01); G01N 1/10 (2013.01); G01N 1/20 (2013.01); G01N 1/38 (2013.01); G01N 21/76 (2013.01); G01N 33/4833 (2013.01); G01N 33/487 (2013.01); G01N 33/582 (2013.01); A61B 5/0084 (2013.01); A61B 5/01 (2013.01); A61B 5/036 (2013.01); A61B 5/14503 (2013.01); A61B 5/14539 (2013.01); A61B 5/14546 (2013.01); A61B 5/14552 (2013.01); A61B 5/42 (2013.01); A61B 10/0038 (2013.01); A61B 2010/0061 (2013.01); A61B 2010/0074 (2013.01); A61B 2562/0233 (2013.01); G01N 2001/1031 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A gastrointestinal tract ingestible device, comprising:
a gastrointestinal tract ingestible housing comprising a chamber;
a composition in the chamber, the composition comprising:
a dye capable of binding to or reacting with a target component of a viable prokaryotic cell from a sample collected from the gastrointestinal tract from an exterior of the housing, wherein the dye exhibits fluorescence that is measurably altered when the dye is bound to or reacted with the target component of the viable prokaryotic cell; and
a reagent capable of selectively lysing eukaryotic cells; and
a system including a light source and a light detector in the housing,
wherein:
the system is configured to detect fluorescence from the reaction of the dye from the chamber and the target component of the viable prokaryotic cell from the sample collected from the gastrointestinal tract from the exterior of the housing.